1519:
1462:
1601:
85:
245:
1567:
1503:
480:
34:
889:
1586:
1560:
1496:
1421:
1090:
1310:
473:
1596:
947:
874:
779:
1553:
1489:
804:
466:
1591:
789:
894:
296:
753:
449:
for "Phase III Efficacy and Safety of MORAb-003 in
Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at
142:
1438:
431:
for "Phase II Efficacy and Safety Study of MORAb-003 in
Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at
532:
997:
292:
1426:
1393:
1334:
1285:
1200:
824:
73:
335:
Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.
1364:
1354:
1324:
1115:
1060:
987:
977:
854:
1339:
1328:
1290:
1180:
1165:
1095:
1075:
1070:
849:
603:
270:
1190:
1050:
819:
784:
1533:
1469:
1305:
1275:
1270:
1255:
1085:
932:
884:
844:
489:
106:
44:
27:
543:
351:
1027:
578:
538:
450:
432:
914:
733:
408:
284:
1537:
1473:
398:
388:
187:
115:
151:
1530:
1526:
1432:
1398:
1065:
403:
376:
274:
1580:
1280:
1135:
688:
523:
288:
1295:
1260:
1245:
1240:
1235:
1230:
1205:
1160:
1155:
1145:
1130:
1017:
992:
972:
834:
799:
738:
718:
528:
513:
458:
445:
427:
1403:
1377:
1372:
1344:
1320:
1315:
1250:
1225:
1215:
1185:
1175:
1140:
1125:
1110:
1100:
1080:
1055:
1040:
1012:
962:
957:
952:
937:
927:
904:
899:
869:
814:
758:
748:
723:
713:
708:
703:
678:
653:
643:
638:
633:
623:
608:
593:
588:
573:
568:
558:
553:
548:
518:
1518:
1461:
1349:
1300:
1265:
1195:
1170:
1120:
1105:
1045:
1035:
1007:
982:
922:
864:
859:
794:
774:
728:
698:
693:
683:
673:
668:
658:
648:
618:
613:
583:
563:
226:
126:
352:
Statement On A Nonproprietary Name
Adopted By The Usan Council - Farletuzumab
20:
1220:
1210:
1002:
967:
942:
879:
839:
829:
809:
743:
663:
628:
598:
377:"Profile of farletuzumab and its potential in the treatment of solid tumors"
324:
49:
412:
498:
61:
393:
56:
318:
171:
162:
462:
273:
of IgG1/κ which is being investigated for the treatment of
1541:
1477:
252:
307:
Farletuzumab uses the following mechanisms of action:
1386:
1363:
1026:
913:
767:
506:
497:
225:
186:
181:
161:
141:
125:
105:
100:
84:
72:
67:
55:
43:
33:
26:
114:
1602:Antineoplastic and immunomodulating drug stubs
317:Inhibition of interaction between FRα and Lyn
1561:
1497:
474:
8:
19:
280:This drug was developed by Morphotek, Inc.
1568:
1554:
1504:
1490:
503:
481:
467:
459:
402:
392:
150:
311:Antibody-dependent cellular cytotoxicity
344:
18:
7:
1515:
1513:
1458:
1456:
370:
368:
366:
364:
323:Induces cell death associated with
170:
1540:. You can help Knowledge (XXG) by
1476:. You can help Knowledge (XXG) by
14:
375:Sato S, Itamochi H (2016-03-07).
314:Complement-dependent cytotoxicity
1517:
1460:
204:
198:
1587:Drugs not assigned an ATC code
216:
210:
192:
1:
297:non-small-cell lung carcinoma
356:American Medical Association
1618:
1512:
1455:
182:Chemical and physical data
1597:Monoclonal antibody stubs
1416:
998:Mirvetuximab soravtansine
293:epithelial ovarian cancer
242:
291:in some cancers such as
1394:Depatuxizumab mafodotin
1335:Tucotuzumab celmoleukin
1286:Rovalpituzumab tesirine
1201:Lorvotuzumab mertansine
1091:Clivatuzumab tetraxetan
381:OncoTargets and Therapy
1472:–related article is a
1355:Vorsetuzumab mafodotin
1311:Tacatuzumab tetraxetan
1116:Denintuzumab mafodotin
1061:Bivatuzumab mertansine
988:Loncastuximab tesirine
978:Indatuximab ravtansine
855:Naptumomab estafenatox
443:Clinical trial number
425:Clinical trial number
1592:Monoclonal antibodies
1340:Vandortuzumab vedotin
1291:Sacituzumab govitecan
1181:Inotuzumab ozogamicin
1166:Gemtuzumab ozogamicin
1096:Cofetuzumab pelidotin
1076:Cantuzumab ravtansine
1071:Cantuzumab mertansine
890:Nofetumomab merpentan
850:Moxetumomab pasudotox
604:Glembatumumab vedotin
490:Monoclonal antibodies
285:folate receptor alpha
80:Intravenous injection
1387:Chimeric + humanized
1191:Lifastuzumab vedotin
1051:Belantamab mafodotin
820:Ibritumomab tiuxetan
785:Anatumomab mafenatox
1470:monoclonal antibody
1306:Sofituzumab vedotin
1276:Polatuzumab vedotin
1271:Pinatuzumab vedotin
1256:Oportuzumab monatox
1086:Citatuzumab bogatox
948:Derlotuximab biotin
933:Brentuximab vedotin
885:Taplitumomab paptox
875:Satumomab pendetide
845:Nacolomab tafenatox
780:Altumomab pentetate
303:Mechanism of action
271:monoclonal antibody
28:Monoclonal antibody
23:
1443:Never to phase III
805:Capromab pendetide
579:Enfortumab vedotin
451:ClinicalTrials.gov
433:ClinicalTrials.gov
394:10.2147/OTT.S98242
283:It is targeted at
1549:
1548:
1485:
1484:
1453:
1452:
1412:
1411:
734:Tisotumab vedotin
269:) is a humanized
260:
259:
16:Chemical compound
1609:
1570:
1563:
1556:
1531:immunomodulatory
1521:
1514:
1506:
1499:
1492:
1464:
1457:
1365:Rat/mouse hybrid
504:
483:
476:
469:
460:
453:
441:
435:
423:
417:
416:
406:
396:
372:
359:
349:
256:
255:
248:
237:
235:
218:
212:
206:
200:
194:
174:
154:
118:
24:
22:
1617:
1616:
1612:
1611:
1610:
1608:
1607:
1606:
1577:
1576:
1575:
1574:
1511:
1510:
1454:
1449:
1448:
1433:Clinical trials
1408:
1382:
1359:
1022:
909:
763:
493:
487:
457:
456:
442:
438:
424:
420:
374:
373:
362:
350:
346:
341:
333:
331:Adverse effects
305:
287:(FRα) which is
251:
249:
246:(what is this?)
243:
233:
231:
221:
215:
209:
203:
197:
177:
157:
137:
121:
96:
75:
17:
12:
11:
5:
1615:
1613:
1605:
1604:
1599:
1594:
1589:
1579:
1578:
1573:
1572:
1565:
1558:
1550:
1547:
1546:
1527:antineoplastic
1522:
1509:
1508:
1501:
1494:
1486:
1483:
1482:
1465:
1451:
1450:
1447:
1446:
1445:
1444:
1441:
1430:
1424:
1418:
1417:
1414:
1413:
1410:
1409:
1407:
1406:
1401:
1399:Duvortuxizumab
1396:
1390:
1388:
1384:
1383:
1381:
1380:
1375:
1369:
1367:
1361:
1360:
1358:
1357:
1352:
1347:
1342:
1337:
1332:
1318:
1313:
1308:
1303:
1298:
1293:
1288:
1283:
1278:
1273:
1268:
1263:
1258:
1253:
1248:
1243:
1238:
1233:
1228:
1223:
1218:
1213:
1208:
1203:
1198:
1193:
1188:
1183:
1178:
1173:
1168:
1163:
1158:
1153:
1148:
1143:
1138:
1133:
1128:
1123:
1118:
1113:
1108:
1103:
1098:
1093:
1088:
1083:
1078:
1073:
1068:
1066:Brontictuzumab
1063:
1058:
1053:
1048:
1043:
1038:
1032:
1030:
1024:
1023:
1021:
1020:
1015:
1010:
1005:
1000:
995:
990:
985:
980:
975:
970:
965:
960:
955:
950:
945:
940:
935:
930:
925:
919:
917:
911:
910:
908:
907:
902:
897:
892:
887:
882:
877:
872:
867:
862:
857:
852:
847:
842:
837:
832:
827:
822:
817:
812:
807:
802:
797:
792:
787:
782:
777:
771:
769:
765:
764:
762:
761:
756:
751:
746:
741:
736:
731:
726:
721:
716:
711:
706:
701:
696:
691:
686:
681:
676:
671:
666:
661:
656:
651:
646:
641:
636:
631:
626:
621:
616:
611:
606:
601:
596:
591:
586:
581:
576:
571:
566:
561:
556:
551:
546:
541:
536:
533:+hyaluronidase
526:
521:
516:
510:
508:
501:
495:
494:
488:
486:
485:
478:
471:
463:
455:
454:
436:
418:
360:
343:
342:
340:
337:
332:
329:
328:
327:
321:
315:
312:
304:
301:
275:ovarian cancer
258:
257:
240:
239:
229:
223:
222:
219:
213:
207:
201:
195:
190:
184:
183:
179:
178:
176:
175:
167:
165:
159:
158:
156:
155:
147:
145:
139:
138:
136:
135:
131:
129:
123:
122:
120:
119:
111:
109:
103:
102:
98:
97:
95:
94:
90:
88:
82:
81:
78:
76:administration
70:
69:
65:
64:
59:
53:
52:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1614:
1603:
1600:
1598:
1595:
1593:
1590:
1588:
1585:
1584:
1582:
1571:
1566:
1564:
1559:
1557:
1552:
1551:
1545:
1543:
1539:
1536:article is a
1535:
1532:
1528:
1523:
1520:
1516:
1507:
1502:
1500:
1495:
1493:
1488:
1487:
1481:
1479:
1475:
1471:
1466:
1463:
1459:
1442:
1440:
1437:
1436:
1434:
1431:
1428:
1425:
1423:
1420:
1419:
1415:
1405:
1402:
1400:
1397:
1395:
1392:
1391:
1389:
1385:
1379:
1376:
1374:
1371:
1370:
1368:
1366:
1362:
1356:
1353:
1351:
1348:
1346:
1343:
1341:
1338:
1336:
1333:
1330:
1326:
1322:
1319:
1317:
1314:
1312:
1309:
1307:
1304:
1302:
1299:
1297:
1294:
1292:
1289:
1287:
1284:
1282:
1281:Rosmantuzumab
1279:
1277:
1274:
1272:
1269:
1267:
1264:
1262:
1259:
1257:
1254:
1252:
1249:
1247:
1244:
1242:
1239:
1237:
1234:
1232:
1229:
1227:
1224:
1222:
1219:
1217:
1214:
1212:
1209:
1207:
1204:
1202:
1199:
1197:
1194:
1192:
1189:
1187:
1184:
1182:
1179:
1177:
1174:
1172:
1169:
1167:
1164:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1142:
1139:
1137:
1136:Enoblituzumab
1134:
1132:
1129:
1127:
1124:
1122:
1119:
1117:
1114:
1112:
1109:
1107:
1104:
1102:
1099:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1079:
1077:
1074:
1072:
1069:
1067:
1064:
1062:
1059:
1057:
1054:
1052:
1049:
1047:
1044:
1042:
1039:
1037:
1034:
1033:
1031:
1029:
1025:
1019:
1016:
1014:
1011:
1009:
1006:
1004:
1001:
999:
996:
994:
991:
989:
986:
984:
981:
979:
976:
974:
971:
969:
966:
964:
961:
959:
956:
954:
951:
949:
946:
944:
941:
939:
936:
934:
931:
929:
926:
924:
921:
920:
918:
916:
912:
906:
903:
901:
898:
896:
893:
891:
888:
886:
883:
881:
878:
876:
873:
871:
868:
866:
863:
861:
858:
856:
853:
851:
848:
846:
843:
841:
838:
836:
833:
831:
828:
826:
823:
821:
818:
816:
813:
811:
808:
806:
803:
801:
798:
796:
793:
791:
788:
786:
783:
781:
778:
776:
773:
772:
770:
766:
760:
757:
755:
752:
750:
747:
745:
742:
740:
737:
735:
732:
730:
727:
725:
722:
720:
717:
715:
712:
710:
707:
705:
702:
700:
697:
695:
692:
690:
689:Pembrolizumab
687:
685:
682:
680:
677:
675:
672:
670:
667:
665:
662:
660:
657:
655:
652:
650:
647:
645:
642:
640:
637:
635:
632:
630:
627:
625:
622:
620:
617:
615:
612:
610:
607:
605:
602:
600:
597:
595:
592:
590:
587:
585:
582:
580:
577:
575:
572:
570:
567:
565:
562:
560:
557:
555:
552:
550:
547:
545:
542:
540:
537:
534:
530:
527:
525:
524:Ascrinvacumab
522:
520:
517:
515:
512:
511:
509:
505:
502:
500:
496:
491:
484:
479:
477:
472:
470:
465:
464:
461:
452:
448:
447:
440:
437:
434:
430:
429:
422:
419:
414:
410:
405:
400:
395:
390:
386:
382:
378:
371:
369:
367:
365:
361:
357:
353:
348:
345:
338:
336:
330:
326:
322:
320:
316:
313:
310:
309:
308:
302:
300:
298:
294:
290:
289:overexpressed
286:
281:
278:
276:
272:
268:
264:
254:
247:
241:
230:
228:
224:
191:
189:
185:
180:
173:
169:
168:
166:
164:
160:
153:
149:
148:
146:
144:
140:
133:
132:
130:
128:
124:
117:
113:
112:
110:
108:
104:
99:
92:
91:
89:
87:
83:
79:
77:
71:
68:Clinical data
66:
63:
60:
58:
54:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1542:expanding it
1524:
1478:expanding it
1467:
1296:Sibrotuzumab
1261:Parsatuzumab
1246:Otlertuzumab
1241:Odronextamab
1236:Ocaratuzumab
1231:Obinutuzumab
1206:Lumretuzumab
1161:Flotetuzumab
1156:Ficlatuzumab
1151:Farletuzumab
1150:
1146:Etaracizumab
1131:Emibetuzumab
1018:Zolbetuximab
993:Margetuximab
973:Girentuximab
835:Minretumomab
800:Blinatumomab
739:Teprotumumab
719:Seribantumab
544:Botensilimab
529:Atezolizumab
514:Adecatumumab
444:
439:
426:
421:
384:
380:
355:
347:
334:
306:
282:
279:
266:
263:Farletuzumab
262:
261:
250:
244:
21:Farletuzumab
1429:from market
1404:Ontuxizumab
1378:Ertumaxomab
1373:Catumaxomab
1345:Vanucizumab
1325:+deruxtecan
1321:Trastuzumab
1316:Tigatuzumab
1251:Onartuzumab
1226:Nimotuzumab
1216:Milatuzumab
1186:Labetuzumab
1176:Imgatuzumab
1141:Epcoritamab
1126:Emactuzumab
1111:Dalotuzumab
1101:Dacetuzumab
1081:Cirmtuzumab
1056:Bevacizumab
1041:Alemtuzumab
1013:Ublituximab
963:Ensituximab
958:Ecromeximab
953:Dinutuximab
938:Carotuximab
928:Bavituximab
905:Tositumomab
900:Tenatumomab
870:Racotumomab
815:Edrecolomab
790:Arcitumomab
759:Zalutumumab
749:Vantictumab
724:Sugemalimab
714:Robatumumab
709:Rilotumumab
704:Ramucirumab
679:Panitumumab
654:Necitumumab
644:Mapatumumab
639:Lucatumumab
634:Lexatumumab
624:Istiratumab
609:Intetumumab
594:Flanvotumab
589:Figitumumab
574:Dusigitumab
569:Duligotumab
559:Daratumumab
554:Conatumumab
549:Cixutumumab
539:Balstilimab
519:Amivantamab
446:NCT00849667
428:NCT00738699
238: g·mol
116:896723-44-7
101:Identifiers
1581:Categories
1350:Veltuzumab
1329:+emtansine
1301:Simtuzumab
1266:Pertuzumab
1196:Lintuzumab
1171:Glofitamab
1121:Elotuzumab
1106:Demcizumab
1046:Axatilimab
1036:Abituzumab
1008:Siltuximab
983:Isatuximab
923:Amatuximab
895:Pintumomab
865:Pemtumomab
860:Oregovomab
795:Bectumomab
775:Abagovomab
729:Tarextumab
699:Radretumab
694:Pritumumab
684:Patritumab
674:Olaratumab
669:Ofatumumab
659:Nesvacumab
649:Narnatumab
619:Iratumumab
614:Ipilimumab
584:Enoticumab
564:Drozitumab
492:for tumors
387:: 1181–8.
339:References
295:(EOC) and
227:Molar mass
152:2O09BG0OWA
127:ChemSpider
107:CAS Number
1439:Phase III
1427:Withdrawn
1221:Naxitamab
1211:Matuzumab
1028:Humanized
1003:Rituximab
968:Futuximab
943:Cetuximab
880:Solitomab
840:Mitumomab
830:Lilotomab
810:Detumomab
754:Votumumab
744:Tovetumab
664:Nivolumab
629:Icrucumab
599:Ganitumab
325:autophagy
267:MORAb-003
74:Routes of
50:Humanized
915:Chimeric
825:Igovomab
413:27022278
253:(verify)
86:ATC code
62:FR-alpha
404:4789847
188:Formula
1422:WHO-EM
411:
401:
319:kinase
172:D09343
57:Target
45:Source
1525:This
1468:This
768:Mouse
507:Human
499:Tumor
1538:stub
1534:drug
1474:stub
409:PMID
214:2020
208:1716
202:9928
196:6466
163:KEGG
143:UNII
134:none
93:none
35:Type
1529:or
399:PMC
389:doi
236:.06
234:371
232:145
1583::
1435::
1327:/
407:.
397:.
383:.
379:.
363:^
354:,
299:.
277:.
220:42
1569:e
1562:t
1555:v
1544:.
1505:e
1498:t
1491:v
1480:.
1331:)
1323:(
535:)
531:(
482:e
475:t
468:v
415:.
391::
385:9
358:.
265:(
217:S
211:O
205:N
199:H
193:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.